Literature DB >> 15488266

Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs.

J Dewulf1, H Laevens, F Koenen, K Mintiens, A de Kruif.   

Abstract

At present, two types of vaccines against classical swine fever (CSF) virus are commercially available: E2 sub-unit marker vaccines and the conventional attenuated live C-strain vaccines. To evaluate the reduction of the horizontal virus transmission, three comparable experiments were carried out in which groups of weaner pigs (vaccinated with a marker vaccine or a C-strain vaccine) were challenged with CSF virus at 0, 7, and 14 days post-vaccination (dpv). Virus transmission was prevented totally when the challenge occurred at 14 dpv with an E2-marker vaccine (0/12 contact pigs positive in virus isolation (VI); R = 0 (0; 1.5)). At 7 dpv, transmission was reduced slightly (5/12 contact pigs positive in VI; R = 1.0 (0.3; 3.0)), whereas at 0dpv, vaccination had no effect on transmission (10/12 contact pigs positive in VI; R = 2.9 (1.5; 10.8)). In the C-strain-vaccinated pigs, no virus transmission was detected even when the challenge was performed at the same day as the vaccination (0/12 contact pigs positive in VI; R = 0 (0; 1.5)).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488266     DOI: 10.1016/j.prevetmed.2004.05.010

Source DB:  PubMed          Journal:  Prev Vet Med        ISSN: 0167-5877            Impact factor:   2.670


  8 in total

1.  Modelling the effectiveness and risks of vaccination strategies to control classical swine fever epidemics.

Authors:  Jantien A Backer; Thomas J Hagenaars; Herman J W van Roermund; Mart C M de Jong
Journal:  J R Soc Interface       Date:  2008-12-03       Impact factor: 4.118

2.  Partial Activation of natural killer and γδ T cells by classical swine fever viruses is associated with type I interferon elicited from plasmacytoid dendritic cells.

Authors:  Giulia Franzoni; Jane C Edwards; Nitin V Kurkure; Daniel S Edgar; Pedro J Sanchez-Cordon; Felicity J Haines; Francisco J Salguero; Helen E Everett; Kikki B Bodman-Smith; Helen R Crooke; Simon P Graham
Journal:  Clin Vaccine Immunol       Date:  2014-07-30

3.  Challenge of pigs with classical swine fever viruses after C-strain vaccination reveals remarkably rapid protection and insights into early immunity.

Authors:  Simon P Graham; Helen E Everett; Felicity J Haines; Helen L Johns; Olubukola A Sosan; Francisco J Salguero; Derek J Clifford; Falko Steinbach; Trevor W Drew; Helen R Crooke
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

Review 4.  The use of vaccines to control pathogen spread in pig populations.

Authors:  Nicolas Rose; Mathieu Andraud
Journal:  Porcine Health Manag       Date:  2017-03-01

5.  Head Start Immunity: Characterizing the Early Protection of C Strain Vaccine Against Subsequent Classical Swine Fever Virus Infection.

Authors:  Ronan R McCarthy; Helen E Everett; Simon P Graham; Falko Steinbach; Helen R Crooke
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

6.  Effect of a DIVA vaccine with and without in-feed use of coated calcium-butyrate on transmission of Salmonella Typhimurium in pigs.

Authors:  Lotte De Ridder; Dominiek Maes; Jeroen Dewulf; Frank Pasmans; Filip Boyen; Freddy Haesebrouck; Estelle Méroc; Stefan Roels; Bregje Leyman; Patrick Butaye; Yves Van der Stede
Journal:  BMC Vet Res       Date:  2013-12-04       Impact factor: 2.741

Review 7.  Immune Responses Against Classical Swine Fever Virus: Between Ignorance and Lunacy.

Authors:  Artur Summerfield; Nicolas Ruggli
Journal:  Front Vet Sci       Date:  2015-05-07

8.  Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge.

Authors:  Rachel Madera; Wenjie Gong; Lihua Wang; Yulia Burakova; Karen Lleellish; Amy Galliher-Beckley; Jerome Nietfeld; Jamie Henningson; Kaimin Jia; Ping Li; Jianfa Bai; John Schlup; Scott McVey; Changchun Tu; Jishu Shi
Journal:  BMC Vet Res       Date:  2016-09-09       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.